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Amylin, a gut-brain axis hormone, and amyloid-beta peptides (Aβ), a major component
of the Alzheimer’s disease (AD) brain, share several features, including similar β-sheet
secondary structures, binding to the same receptor and being degraded by the same
protease, insulin degrading enzyme (IDE). However, while amylin readily crosses the
blood brain barrier (BBB) and mediates several activities including improving glucose
metabolism, relaxing cerebrovascular structure, modulating inflammatory reaction and
perhaps enhancing neural regeneration, Aβ has no known physiological functions. Thus,
abundant Aβ in the AD brain could block or interfere with the binding of amylin to its
receptor and hinder its functions. Recent studies using animal models for AD demonstrate
that amylin and its analog reduce the AD pathology in the brain and improve cognitive
impairment in AD. Given that, in addition to amyloid plaques and neurofibrillary tangles,
perturbed cerebral glucose metabolism and cerebrovascular damage are the hallmarks of
the AD brain, we propose that giving exogenous amylin type peptides have the potential to
become a new avenue for the diagnosis and therapeutic of AD. Although amylin’s property
of self-aggregation may be a limitation to developing it as a therapeutic for AD, its clinical
analog, pramlintide containing 3 amino acid differences from amylin, does not aggregate
like human amylin, but more potently mediates amylin’s activities in the brain. Pramlintide
is an effective drug for diabetes with a favorable profile of safety. Thus a randomized,
double-blind, placebo-controlled clinical trial should be conducted to examine the efficacy
of pramlintide for AD. This review summarizes the knowledge and findings on amylin type
peptides and discuss pros and cons for their potential for AD.
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INTRODUCTION
As the number of Alzheimer’s disease (AD) patients grows rapidly
in the U.S and globally, the need to find effective treatments for
the disease becomes more urgent. Currently there are only a few
medications prescribed that delay cognitive decline in AD, but
their effects are modest and do not modify the underlying dis-
ease process. From the perspective of drug discovery, while it
is still important to target the core pathology of AD, e.g., amy-
loid plaques and tauopathy in the brain, it may also be beneficial
and effective to treat the downstream of the pathological cascade,
including perturbed glucose metabolism, damaged cerebrovas-
culature, and imbalanced inflammatory reaction, which causes
neuronal death and inhibit neuronal regeneration. Our recent
study found that treatment with amylin, a gut-brain axis peptide,
reduces the AD pathology and improves cognitive impairment
in animal models for AD. This review article will summarize the
research data and knowledge including our own on amylin, and
propose a hypothesis that amylin class peptides can be a poten-
tial treatment for AD. Meanwhile, we will discuss the tendency of
amylin to form aggregation in type 2 diabetes. The goal of this
review is to debate benefit vs. harm of amylin type peptides for
the treatment of AD.
PANCREATIC PEPTIDE AMYLIN
Amylin (also known as islet amyloid polypeptide, or IAPP) is a
37–amino acid peptide hormone, and its gene is encoded on chro-
mosome 12 and highly conserved in mammals during evolution
(Nishi et al., 1989; Chang et al., 2004). While amylin is mainly
produced and secreted by the β-cells in the pancreas (Westermark
et al., 1987), its expression occurs in other locations such as
the gut (Mulder et al., 1994) and in the sensory nervous system
(Mulder et al., 1995).
Amylin peptide is stored together with insulin in dense core
secretory granules in the pancreas (Lukinius et al., 1989). It is
secreted in response to diet/nutrient intake (Vine et al., 1998)
and exercise (Kraemer et al., 2002) stimuli, and displays a pro-
file similar to that of insulin. The peptide circulates in a non-
glycosylated (50%) and a glycosylated form (Nyholm et al., 1998),
the former being the biological active compound. In healthy
humans, fasting plasma amylin concentrations are in the range
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 186 | 1
AGING NEUROSCIENCE
Qiu and Zhu Amylin and Alzheimer’s disease
of 4–25 pmol/l, and amylin is distributed equally to insulin in
plasma and interstitial fluids. Unlike insulin, amylin is not elim-
inated significantly in the liver (Kautzky-Willer et al., 1994) but
mainly through renal metabolism (Hoppener et al., 2000).
Amylin belongs to the calcitonin gene peptide super-
family consisting of calcitonin (CT), calcitonin gene-related
peptide (CGRP) and adrenomedullin in addition to amylin
(Wimalawansa, 1997). These peptides bind to the calcitonin
receptor (CTR) complexed with different receptor-activity-
modifying protein (RAMPs) (Gebre-Medhin et al., 2000). As
amylin readily crosses the blood brain barrier (BBB) (Banks et al.,
1995; Banks and Kastin, 1998; Olsson et al., 2007), CTR and
RAMPs are highly expressed in the brain. Individual RAMPs have
been disrupted revealing a range of phenotypes. Mice with a
disrupted RAMP1 gene were hypertensive and exhibited a dys-
regulated immune response, while removal of RAMP2 was lethal,
and RAMP3 knockout mice appeared normal until old age when
they were not as heavy as their wild-type littermates (Sexton et al.,
2009). It is shown that herodimers between the CTR and RAMP1
or RAMP3 preferentially bind amylin (Christopoulos et al., 1999).
AMYLIN REDUCES THE AD PATHOLOGY AND IMPROVES COGNITIVE
IMPAIRMENT IN THE ANIMAL MODELS FOR AD
Amyloid-β peptide (Aβ is a major component of AD pathology
in the brain (Hardy and Selkoe, 2002). Amylin and Aβ share
several features, including similar β-sheet secondary structures
(Lim et al., 2008), binding to the same amylin receptor (Fu et al.,
2012) and being degraded by Qiu et al. (1998); Bennett et al.
(2003); Shen et al. (2006) or bound to insulin degrading enzyme
(IDE) (de Tullio et al., 2013). Since amylin readily crosses the
BBB (Banks et al., 1995; Banks and Kastin, 1998; Olsson et al.,
2007), our team studied peripheral amylin’s action on the amyloid
pathology of AD in the brain.
Using amyloid precursor protein (APP) transgenic mice, we
surprisingly found that chronic intraperitoneal (i.p.) injection
of AD animals with both amylin and its analog, pramlintide,
reduces the amyloid burden as well as lowers the concentrations
of Aβ (Figure 1) (Zhu et al., 2014). These treatments signifi-
cantly improve learning and memory in these mice as assessed
by two behavioral tests, Y maze and Morris water maze. Similar
to the finding by Adler et al. (2014), our unpublished data also
found that elders who had mild cognitive impairment (MCI) or
AD had lower concentrations of plasma amylin than controls in
the absence diabetes (Table 1). Further, we found that increas-
ing quartiles of plasma amylin were positively associated with
the test scores of memory, visuospacial and executive function,
but not with those of language and attention, after adjusting for
demographic information, ApoE4 allele, diabetes, stroke, kidney
function, and lipid profile (Table 2) (submitted and in revision).
Given that impairments in these cognitive domains are signature
symptoms of an early stage of AD (Weintraub et al., 2009), both
mouse and human studies suggest that amylin, natural or syn-
thetic, are likely to reduce the AD pathology in the brain and
provides a new avenue of treatment for the disease.
To understand how amylin type peptides improve cognition
in the AD mice, our mechanistic study revealed that amylin type
peptides enhance the removal of neurotoxic Aβ out of the brain.
Table 1 | Comparisons of plasma amylin in humans in the absence of
diabetes.
Diagnoses Controls MCI Alzheimer’s disease
N = 104 N = 82 N = 26
Median, pM/L 23.5 14.8 17.6
Q1, Q3 13.3, 47.8 8.3, 31.7 7.9, 27.9
p-values – 0.01 0.05
Median (Q1, Q3) is used to describe the distributions of plasma amylin. Using
Wilcoxon rank sum test, the comparisons are shown between a disease
subgroup and the controls.
FIGURE 1 | Amylin treatment of 5XFAD mice reduces the amyloid
burden and improves their learning and memory. At 3.5 months of
age, 5XFAD mice were treated by i.p. injection of PBS or amylin
(200 pg/kg) daily for 10 weeks (n = 10 per group). (A) Dense-cored Aβ
plaque burden is reduced in the whole brain including the cerebral
cortex and the hippocampus. The amylin treated 5XFAD mice illustrated
improved cognition by showing increased percent alternation in the Y
maze test (B) (p = 0.001) and by showing shortened times in Morris
water maze test (C) in finding the hidden platform at day 10 (D10)
(p = 0.005), in memory at day 12 (D12) after the completion of training
and skipping day 11 (p = 0.002), and in the probe trial (p = 0.03). Mean
± SE was used with ∗∗p < 0.01.
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Table 2 | Comparisons of functions in cognitive domains across amylin quartiles.
Amylin quartiles Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-values
GENERAL COGNITION
MMSE Scores, Mean ± SD 24.7±4.0 25.1±3.3 25.5±3.3 25.3±3.3 0.15
LANGUAGE
Verbal fluency, Mean ± SD 26.9±16.3 26.4±12.9 28.8±12.6 27.8±12.0 0.17
ATTENTION AND CONCENTRATION
Digit span, Mean ± SD 13.6±3.8 13.5±3.7 14.1±3.6 13.9±3.8 0.25
MEMORY
WLL delayed recall, Mean ± SD 3.4±2.7 3.2±2.7 4.1±2.9 3.8±2.8 0.002
LM delayed recall, Mean ± SD 17.4±10.2 16.8±9.7 19.9±9.6 19.4±9.3 0.0002
VISUOSPATIAL AND EXECUTIVE FUNCTION
Trailmaking A, Mean ± SD 98.8±66.6 93.7±70.3 78.2±45.9 78.7±53.0 < 0.0001
Trailmaking B, Mean ± SD 223.0±80.4 215.1±84.1 205.0±83.7 204.1±86.1 0.04
Block design, Mean ± SD 18.7±8.9 19.3±8.8 20.6±8.8 21.5±8.7 0.004
Mean ± SD with ANOVA test is used to describe the distributions and comparisons of test scores in each cognitive domain across the amylin quartiles. p-values for
the statistical significance are shown. MMSE, Mini Mental State Exam; WLL, Word learning list; LM, Logical memory.
FIGURE 2 | The hypothesis of amylin type peptides as a novel
therapeutic and a diagnostic tool for AD. Since amylin and Aβ share a
secondary β-sheet structure, we hypothesize that abundant Aβ in the AD
brain may block amylin from binding to its receptor and hinder normal amylin
functions in the brain. Thus giving extra amylin type peptides not only
removes Aβ out of the brain to reduce the AD pathology in the brain, but also
may restore/repair the impaired functions in the downstream of Aβ pathway
in AD.
Both amylin and pramlintide treatments increase the concentra-
tions of Aβ1-42 in cerebral spinal fluid (CSF) while reducing the
amount of Aβ in the brain. A single i.p. injection of either amylin
or pramlintide induces a surge of Aβ in serum, the magnitude of
which is proportionate to the amount of Aβ in the brain tissue.
One intracerebroventricular (i.c.v.) injection of amylin induces
a more significant surge in serum Aβ than one i.p. injection
of the peptide. Thus amylin treatment results in the translo-
cation of Aβ from the brain into the CSF and blood probably
through its effects on cerebral vasculature (Westfall and Curfman-
Falvey, 1995; Edvinsson et al., 2001). If our mouse findings that
amylin removes Aβ from the brain were relevant to humans, we
would expect amylin to be positively associated with Aβ in human
plasma samples. Indeed, using human fasting plasma samples,
we found that concentrations of Aβ1-42 (P < 0.0001) and Aβ1-
40 (P < 0.0001) increased with each quartile increase of amylin
(Qiu et al., 2014) after adjusting for age, gender, ethnicity, ApoE4,
BMI, diabetes, stroke, kidney function and lipid profile. Given
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that there is abundant Aβ in the AD brain, a stronger positive
association between amylin and Aβ1-42 as well as Aβ1-40 was
found in patients with AD or amnestic MCI than the one found
in elderly with normal cognition (Table 3). Figure 2 shows our
hypothesis that abundant Aβ, in either monomeric, oligomeric or
fibriller form, in the AD brain may block the ability of amylin to
bind to its receptor and interefere with normal amylin functions
in the brain; giving exogenous amylin class peptides could rescue
the amylin activities in the brain as well as removing Aβ out of the
brain.
Independently, Adler et al., used pramlintide to treat another
AD mouse model, SAMP8, which have increased amount of Aβ
and other AD pathology (Adler et al., 2014). They found that
pramlintide treatment improved the performance of these mice
in the novel object recognition task. Their study demonstrated
that the pramlintide-treated mice had increased expression of
the synaptic marker synapsin I and the kinase cyclin-dependent
kinase-5 in the hippocampus, as well as decreased oxidative stress
and inflammatory markers in the hippocampus. Thus the effects
of amylin type peptides for AD extend beyond just the removal of
Aβ from the brain, distinct from the targets of current AD drug
discovery (Dunkel et al., 2012).
OTHER AMYLIN ACTIVITIES THAT ARE POTENTIALLY BENEFICIAL FOR
AD
Since the first description of amylin 25 years ago (Cooper et al.,
1987; Westermark et al., 1987), a large body of data has doc-
umented the physiological actions of this peptide in the brain
(Roth, 2013). In contrast to amylin, there is no known phys-
iological function of Aβ in brain. Aβ in the AD brain might
interfere with the following functions mediated by amylin,
and thus giving extra amylin type peptides may restore/repair
them.
Amylin improves glucose metabolism
Multiple imaging studies have demonstrated perturbed cerebral
glucose metabolism in the AD brain (Johnson et al., 2012).
Amylin is an important hormone regulating glucose metabolism
in the body (Min et al., 2011; Roth, 2013). Since it readily crosses
the BBB, and the brain accounts for approximately 50% of the
body’s glucose use (Bryant et al., 2002), amylin may play a simi-
lar role in the brain. Abundant Aβ in the AD brain may block or
interfere with this activity of amylin.
Amylin regulates glucose metabolism in the body through
three primary mechanisms in the brain, (1) slowing the rate of
gastric emptying, (2) suppressing post-meal glucagon secretion
and (3) reducing food intake (Roth et al., 2012; Roth, 2013).
Amylin acts on the area postrema (AP), nucleus of the solitary
tract (NTS), lateral parabrachial nucleus and the central nucleus
of the amygdala in the brain to mediate these activities (Boyle and
Lutz, 2011; Roth, 2013). Aspiration of the AP abolishes amylin’s
effects on gastric emptying (Young, 2005; Wickbom et al., 2008).
Antagonism of amylin receptors with AC187 increases food intake
and abrogates the anorexigenic effects of exogenous peripheral
amylin (Mollet et al., 2004). Amylin’s activity in these brain areas
is mediated through inducing c-Fos expression (Rowland et al.,
1997).
Amylin knock-out mice do not show any differences in basal
insulin and glucose concentrations compared to wild types
throughout development (Gebre-Medhin et al., 1998a), and
there are also no differences in body weight, body composi-
tion or plasma leptin concentrations observed when mice are
maintained on a low-fat diet (6 weeks) (Turek et al., 2010).
Consistently, global deletion of the CTR has no effects on body
weight or metabolic disease-related endpoints (Davey et al.,
2008). Some studies reported that amylin stimulates insulin secre-
tion (Fehmann et al., 1990), while another one demonstrated
that amylin inhibits insulin secretion when the concentration of
insulin is high (Gebre-Medhin et al., 2000). It should be noted
that in response to changes in ambient glucose concentrations
in vivo, amylin and insulin mRNA expressions appear to be reg-
ulated in parallel (Alam et al., 1992). Using amylin null mice
(Gebre-Medhin et al., 1998a) and amylin transgenic mice (Ahren
et al., 1998), it is shown that amylin plays a major role in inhibit-
ing insulin secretion by pancreas and decreasing glucose tolerance
after a glucose loading. All these researches suggest that amylin is
probably not a homeostasis peptide to maintain metabolism in
the body, but it is more likely a regulatory peptide responding to
metabolic or other environmental stimuli.
Amylin promotes cell growth
It has been proposed that amylin may play a role as a trophic
factor (Potes and Lutz, 2010). Amylin is shown to stimulate
osteoblast growth (Cornish et al., 1998). After injection of alloxan,
more severe diabetes and β cell damage/dysfunction were devel-
oped in amylin null mice than in the wild typemice (Mulder et al.,
Table 3 | Correlations between Aβ and Amylin in Plasma in Humans.
Diagnoses Controls Amnestic MCI Alzheimer’s disease
N = 145 N = 16 N = 42
Age, year, Mean ± SD* 72.3 ± 8.0 75.7 ± 8.7 80.5 ± 8.1
MMSE, Mean ± SD* 27.1 ± 2.6 26.4 ± 2.5 22.2 ± 3.3
Log10 Amylin with Log10 Aß1-42 r = +0.06, p = 0.46 r = +0.73, p = 0.001 r = +0.52, p = 0.0004
Log10 Amylin with Log10 Aß1-40 r = +0.02, p = 0.83 r = +0.58, p = 0.02 r = +0.29, p = 0.06
Using ANOVA analysis, age and average Mini Mental State Exam (MMSE) scores in the subgroups of the controls, amnestic mild cognitive impairment (amnestic
MCI) and Alzheimer’s disease are compared. *p < 0.0001. Pearson analyses were performed to determine correlation coefficient between plasma Aβ40 or Aβ42
and amylin in different subgroups: the controls, amnestic MCI and Alzheimer’s disease. p-values for statistical significance are shown.
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2000), probably due to the lack of amylin to promote growth and
regeneration of cells after the insult (Gebre-Medhin et al., 2000).
Amylin deficient mice showed reduced pain reaction when chal-
lenged with formalin, suggesting an essential role of amylin in the
function of sensory neurons (Gebre-Medhin et al., 1998b; Mulder
et al., 1999). Additionally, amylin infusion enhanced neurogen-
esis in the hippocampus and the area postrema in the brain of
rodents with ovariectomy and improved their immobility in the
forced swim test (Trevaskis et al., 2010). Amylin may be involved
in the formation of synapsis by inducing the expression of synap-
sis I and cdk5 (Adler et al., 2014). The neuronal protective activity
of amylin under pathological insults can be beneficial to reversing
the effects of neuronal degeneration.
Amylin modulates inflammatory process
Human amylin has been shown to be a modulator of inflamma-
tion, especially activation of the NLRP3 inflammasome, periph-
erally (Masters et al., 2010). Mice with a disrupted RAMP1 gene
exhibited a dysregulated immune response (Sexton et al., 2009).
Amylin induces production of interleukin 1β (IL-1β) through
CD36 receptor (Sheedy et al., 2013). Human amylin, but not
rat amylin or Aβ, stimulates the release of the gradulocyte-
macrophage colony-stimulating factor (G-MCSF) in eosinophils,
and inhibits the in vitro interleukin-5 (IL-5)-mediated survival
of eosinophils (Hom et al., 1995). After unilateral adjuvant-
induced inflammation, expression of amylin is upregulated in
innervating sensory neurons and is involved in the the inflam-
matory response (Mulder et al., 1997). In inflammatory mod-
els characterized with a vascular component including mouse
ear oedema induced by croton oil and acetic acid-induced
peritonitis, amylin exerts anti-inflammatory activity (Clementi
et al., 1995). All these data demonstrate that amylin is a mod-
ulator in peripheral inflammation. Whether or not and how
amylin modulates neuroinflammation in the brain are not yet
known.
Amylin and Aβ mediate different intracellular signal transduction
Despite the fact that amylin and Aβ bind to the same amylin
receptor (Fu et al., 2012), a recent study shows that while amylin
and pramlintide increase intracellular cAMP, an important sec-
ondary messenger for learning, memory and mood, Aβ1-42 does
not influence intracellular cAMP (Gingell et al., 2014). The data
suggest that amylin and Aβ do not mediate the same physio-
logical function within cells. Additionally, amylin activates the
extracellular-signal regulated kinase ½ (ERK1/2) pathway by
inducing the phosphorylation of ERK1/2 (pERK) (Potes et al.,
2012); in contrast, Aβ decreases pERK in neurons, leading to the
generation of toxic tau phosphorylation and fragments (Reifert
et al., 2011). A recent study shows that amylin treatment can
increase glutamate release enough to cause cell firing (Fukuda
et al., 2013), which may be necessary for restoring learning and
memory in AD (Danysz and Parsons, 2012).
AMYLIN’S SELF AGGREGATION FEATURE UNDER PATHOLOGICAL
CONDITIONS
The amylin amyloid deposits were first found in the pancreas in
diabetic patients in Opie (1901). These amylin aggregates disrupt
islet structure and contribute to the β cell dysfunction in most
type 2 diabetes patients (Hoppener et al., 1994; Hull et al., 2004).
On the other hand, the Aβ aggregation and amyloid plaques are
identified as a hallmark pathology in the AD brain and have been
thought to be a key element in the AD pathogenesis (Hardy and
Selkoe, 2002). Although amylin and Aβ have little or no amino
acid sequence homology, the core structure of the fibrils from
their amyloids is essentially the same (Sunde et al., 1997). A recent
study found an accumulation of amylin amyloid in the cere-
brovascular system in the AD brain (Jackson et al., 2013). It is
possible that the pathological environment of the AD brain causes
any amyloidgenic peptides, including amylin, to aggregate and
become cell toxic.
The mechanism(s) responsible for amylin amyloid formation
in type 2 diabetes is still unclear, but it appears that an increase in
the secretion of amylin, per se, is not sufficient to form aggregates
and amyloids. The heterozygous transgenic mice that produce a
large amount of human amylin do not develop islet amyloids, and
only some, but not all, homozygous mice develop this pancreatic
pathology (Hoppener et al., 1999), which requires extrapancreatic
and environmental factors such as high-glucose or high-fat feed-
ing to occur (Hull et al., 2003; Andrikopoulos et al., 2004). These
factors, which can promote the formation of amylin amyloids,
include the following: (1) insulin resistance like hyperglycemia
(de Koning et al., 1994), (2) the ob gene introduction (Hoppener
et al., 1999), or (3) glycosylation of amylin (Kapurniotu et al.,
1998). Notably, the changed ratio of amylin to insulin in plasma
induced by diet or other experimental stimulations is related to
the formation amylin amyloid in the pancreas (Gebre-Medhin
et al., 2000).
FUTURE PERSPECTIVES IN DEVELOPING AMYLIN TYPE PEPTIDES AS A
TREATMENT FOR AD
Although amylin’s self-aggregation property under the pathlogi-
cal conditions (Pillay and Govender, 2013) may affect its devel-
opment as a drug for AD, several studies demonstrate that amylin
can inhibit Aβ aggregate, as they can form the cross-interactions
(Andreetto et al., 2010; Seeliger et al., 2012). Monomeric amylin
and its analogs inhibit the formation of Aβ aggregation in vitro
(Yan et al., 2007, 2013, 2014; Sellin et al., 2010; Andreetto et al.,
2011). It is shown that amylin with the methylation at N-terminal
region is highly soluble and inhibits the aggregation of Aβ40
(Yan et al., 2007, 2013; Sellin et al., 2010). N-terminal region of
amylin is critical for inhibiting Aβ fribrillogenesis and cell toxicity
through Aβ-amylin interaction (Andreetto et al., 2011). As the Aβ
oligomer is a key element in the AD pathogenesis (Selkoe, 2008),
that Aβ-amylin hetero-oligomers are not cytotoxic (Yan et al.,
2014) may be another mechanism to reduce amyloid pathology in
the brain. Rodent amylin also shows an ability to inhibit forma-
tion of fibrils from human amylin (Westermark et al., 2000), and
can not induce cell apoptosis like human amylin after incubating
for 48 h (Ritzel et al., 2007).
The debate of over 10 years ago on whether amylin is benefi-
cial or harmful to the treatment of type 2 diabetes (Gebre-Medhin
et al., 2000) may provide a lesson for drug development for AD.
Since the clinical utility of human amylin is limited by a propen-
sity for self-aggregation despite its activity of inhibiting appetite
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and regulating glucose metabolism, that limitation was overcome
by the substitution of prolines at positions 25, 28 and 29 of human
amylin based on rat amylin sequences (Colburn et al., 1996;
Moriarty and Raleigh, 1999). This resulted in a synthetic amyli-
nomimetic peptide, pramlintide, with improved stability and
decreased potential for aggregation and pramlintide has become a
potent anti-diabetic drug (Pencek et al., 2010). Pharmacokinetic
studies show that the terminal half-life of amylin in rats is
∼13min and that the half-life for pramlintide in humans is ∼20–
45min (Colburn et al., 1996; Young, 2005). Pramlintide has a
favorable safety profile in clinical use, and only nausea is the
most common tolerability-related adverse event (Aronne et al.,
2007).
Since pramlintide is a relatively new drug for diabetes, there
are no available data on the association between pramlintide use
and AD yet. However, some medications, which are shown to
influence the concentration of amylin in blood, are associated
with cognitive function in humans. For example, metformin is
shown to lower serum amylin concentrations in patients with
type 2 diabetes (Zapecka-Dubno et al., 1999), and use of met-
formin may be associated with cognitive impairment (Moore
et al., 2013) and increased risk of AD development (Imfeld et al.,
2012). In contrast, another drug sulfonylurea does not affect
serum amylin concentrations (Rachman et al., 1998), and is found
not associated with the risk of AD. One animal study shows that
sulfonylurea treatment reduces the AD pathology in the brain
(Baraka and ElGhotny, 2010).
While many papers in the AD field have been focused on
amylin’s self-aggregation like Aβ (Gotz et al., 2009; DeToma et al.,
2012), probably equal attention needs to be given to the poten-
tial benefits of soluble amylin or its non-amyloidgenic analogs for
the AD brain. The research findings that amylin readily crosses
the BBB, mediates important brain functions and mimics the
Aβ structure so that they can antagonize each other are hard to
ignore, taken together. Based on ours and Adler et al.,’s studies,
it is hypothesized that this old foe, amylin, or its analogs may
become a new friend for AD. More basic researches are needed
to understand the mechanism of amylin’s effects in the AD brain
and probably to search for better analogs of it. Ultimately, whether
amylin type peptides can be a new and novel avenue of thera-
peutic for AD should only be concluded through a double blind,
placebo controlled clinical trial in humans.
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